- Home
- NVRI vs CGEM Comparison
NVRI vs CGEM Comparison
Compare NVRI & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVRI
- CGEM
- Stock Information
- Founded
- NVRI 1853
- CGEM 2016
- Country
- NVRI United States
- CGEM United States
- Employees
- NVRI N/A
- CGEM N/A
- Industry
- NVRI Diversified Commercial Services
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- NVRI Miscellaneous
- CGEM Health Care
- Exchange
- NVRI Nasdaq
- CGEM Nasdaq
- Market Cap
- NVRI 521.3M
- CGEM 506.1M
- IPO Year
- NVRI N/A
- CGEM 2021
- Fundamental
- Price
- NVRI $6.13
- CGEM $8.38
- Analyst Decision
- NVRI Hold
- CGEM Strong Buy
- Analyst Count
- NVRI 1
- CGEM 7
- Target Price
- NVRI $10.00
- CGEM $32.86
- AVG Volume (30 Days)
- NVRI 797.3K
- CGEM 536.2K
- Earning Date
- NVRI 05-01-2025
- CGEM 05-14-2025
- Dividend Yield
- NVRI N/A
- CGEM N/A
- EPS Growth
- NVRI N/A
- CGEM N/A
- EPS
- NVRI N/A
- CGEM N/A
- Revenue
- NVRI $2,342,645,000.00
- CGEM N/A
- Revenue This Year
- NVRI N/A
- CGEM N/A
- Revenue Next Year
- NVRI $3.60
- CGEM N/A
- P/E Ratio
- NVRI N/A
- CGEM N/A
- Revenue Growth
- NVRI N/A
- CGEM N/A
- 52 Week Low
- NVRI $4.72
- CGEM $6.85
- 52 Week High
- NVRI $12.79
- CGEM $30.19
- Technical
- Relative Strength Index (RSI)
- NVRI 49.33
- CGEM 55.85
- Support Level
- NVRI $5.59
- CGEM $7.38
- Resistance Level
- NVRI $5.95
- CGEM $8.10
- Average True Range (ATR)
- NVRI 0.46
- CGEM 0.53
- MACD
- NVRI 0.08
- CGEM 0.14
- Stochastic Oscillator
- NVRI 75.95
- CGEM 78.87
About NVRI Enviri Corporation
Enviri Corp is a market-leading, provider of environmental solutions for industrial and specialty waste streams, and equipment and technology for the rail sector. The company's current operations consist of three divisions: Harsco Environmental, Harsco Rail, and Clean Earth. The company gains its revenue from Harsco Environmental segment. Geographically company operates in USA and International Countries, with majority revenue from USA.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.